

# Kang-Yi Su

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5524897/publications.pdf>

Version: 2024-02-01

73  
papers

2,619  
citations

218677

26  
h-index

197818

49  
g-index

75  
all docs

75  
docs citations

75  
times ranked

4797  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pretreatment Epidermal Growth Factor Receptor (<i>EGFR</i>) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 433-440.	1.6	471
2	Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression. <i>Cell</i> , 2020, 182, 226-244.e17.	28.9	178
3	Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1071-1079.	5.6	148
4	Enterovirus-Induced miR-141 Contributes to Shutoff ofÂHost Protein Translation by Targeting the Translation Initiation Factor eIF4E. <i>Cell Host and Microbe</i> , 2011, 9, 58-69.	11.0	148
5	Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. <i>Lancet Respiratory Medicine</i> ,the, 2018, 6, 107-116.	10.7	121
6	Identification of Five Driver Gene Mutations in Patients with Treatment-NaÃ“ve Lung Adenocarcinoma in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0120852.	2.5	88
7	Mice Deficient in Collapsin Response Mediator Protein-1 Exhibit Impaired Long-Term Potentiation and Impaired Spatial Learning and Memory. <i>Journal of Neuroscience</i> , 2007, 27, 2513-2524.	3.6	85
8	R331W Missense Mutation of Oncogene <i>YAP1</i> Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability. <i>Journal of Clinical Oncology</i> , 2015, 33, 2303-2310.	1.6	77
9	Rutin, a Flavonoid and Principal Component of <i>Saussurea Involucrata,</i> Attenuates Physical Fatigue in a Forced Swimming Mouse Model. <i>International Journal of Medical Sciences</i> , 2014, 11, 528-537.	2.5	67
10	Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 603-610.	1.1	64
11	Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2016, 94, 46-53.	2.0	60
12	High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naÃ“ve advanced EGFR-mutant lung adenocarcinoma patients. <i>Lung Cancer</i> , 2019, 127, 37-43.	2.0	60
13	EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 98384-98393.	1.8	58
14	Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. <i>European Journal of Cancer</i> , 2020, 124, 110-122.	2.8	56
15	The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2018, 50, 1294-1303.	3.0	49
16	Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 125, 282-290.	2.0	48
17	3,4-Dihydroxytoluene, a metabolite of rutin, inhibits inflammatory responses in lipopolysaccharide-activated macrophages by reducing the activation of NF-Î“B signaling. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 21.	3.7	44
18	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. <i>Journal of Cancer</i> , 2018, 9, 1813-1820.	2.5	41

#	ARTICLE	IF	CITATIONS
19	Shisa3 Is Associated with Prolonged Survival through Promoting $\beta$ -Catenin Degradation in Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 433-444.	5.6	34
20	Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma With EGFR-Activating Mutations. Journal of Clinical Oncology, 2011, 29, 3435-3442.	1.6	33
21	Potential Therapeutic Role of Hispidulin in Gastric Cancer through Induction of Apoptosis via NAG-1 Signaling. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-12.	1.2	33
22	Rutin, a Flavonoid That Is a Main Component of <i>Saussurea involucrata</i> , Attenuates the Senescence Effect in D-Galactose Aging Mouse Model. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-10.	1.2	30
23	HoxA5 Inhibits Metastasis via Regulating Cytoskeletal Remodelling and Associates with Prolonged Survival in Non-Small-Cell Lung Carcinoma. PLoS ONE, 2015, 10, e0124191.	2.5	30
24	Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients. Journal of Immunotherapy, 2018, 41, 292-299.	2.4	30
25	JAG1 Is Associated with Poor Survival through Inducing Metastasis in Lung Cancer. PLoS ONE, 2016, 11, e0150355.	2.5	29
26	Taiwanese Green Propolis and Propolis G Protect the Liver from the Pathogenesis of Fibrosis via Eliminating TGF- $\beta$ -Induced Smad2/3 Phosphorylation. Journal of Agricultural and Food Chemistry, 2014, 62, 3192-3201.	5.2	28
27	SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung adenocarcinoma. Oncotarget, 2016, 7, 44417-44429.	1.8	28
28	Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells by hepatocyte growth factor signaling in mice. Hepatology, 2012, 56, 1913-1923.	7.3	27
29	The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M. Oncotarget, 2016, 7, 48059-48069.	1.8	24
30	FAM198B Is Associated with Prolonged Survival and Inhibits Metastasis in Lung Adenocarcinoma via Blockage of ERK-Mediated MMP-1 Expression. Clinical Cancer Research, 2018, 24, 916-926.	7.0	23
31	ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Scientific Reports, 2020, 10, 21063.	3.3	21
32	Molecular gene signature and prognosis of non-small cell lung cancer. Oncotarget, 2016, 7, 51898-51907.	1.8	21
33	Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 753-766.	5.6	20
34	Decreased expressions of hepsin in human hepatocellular carcinomas. Liver International, 2006, 26, 774-780.	3.9	19
35	EGFR mutation and lobar location of lung adenocarcinoma. Carcinogenesis, 2016, 37, 157-162.	2.8	19
36	Perinatal polychlorinated biphenyls and polychlorinated dibenzofurans exposure are associated with DNA methylation changes lasting to early adulthood: Findings from Yucheng second generation. Environmental Research, 2019, 170, 481-486.	7.5	19

#	ARTICLE	IF	CITATIONS
37	Rapid Sputum Multiplex Detection of the <i>M. tuberculosis</i> Complex (MTBC) and Resistance Mutations for Eight Antibiotics by Nucleotide MALDI-TOF MS. <i>Scientific Reports</i> , 2017, 7, 41486.	3.3	17
38	Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma. <i>PLoS ONE</i> , 2018, 13, e0207001.	2.5	17
39	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , 2020, 25, 702-711.	3.7	17
40	Gene expression of MAGEA3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e212-e223.	1.1	16
41	Novel therapeutic drug identification and gene correlation for fatty liver disease using high-content screening: Proof of concept. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 121, 106-117.	4.0	15
42	Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 799.	2.0	14
43	Improved Dried Blood Spot-Based Metabolomics Analysis by a Postcolumn Infused-Internal Standard Assisted Liquid Chromatography-Electrospray Ionization Mass Spectrometry Method. <i>Analytical Chemistry</i> , 2019, 91, 10702-10712.	6.5	14
44	Metabolomics Investigation of Voriconazole-Induced Hepatotoxicity in Mice. <i>Chemical Research in Toxicology</i> , 2019, 32, 1840-1849.	3.3	13
45	PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. <i>Scientific Reports</i> , 2022, 12, .	3.3	13
46	R26R-GR: A Cre-Activable Dual Fluorescent Protein Reporter Mouse. <i>PLoS ONE</i> , 2012, 7, e46171.	2.5	12
47	Potential Therapeutic Role of Z-Isochailulactone in Lung Cancer through Induction of Apoptosis via Notch Signaling. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-11.	1.2	12
48	Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinical Practice. <i>Scientific Reports</i> , 2016, 6, 30944.	3.3	12
49	Dichloromethane extracts of propolis protect cell from oxygen-glucose deprivation-induced oxidative stress via reducing apoptosis. <i>Food and Nutrition Research</i> , 2016, 60, 30081.	2.6	11
50	Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100140.	1.1	11
51	Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma. <i>PLoS ONE</i> , 2014, 9, e107160.	2.5	11
52	Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment. <i>Oncology</i> , 2021, 99, 32-40.	1.9	9
53	The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2022, 54, 434-444.	3.0	9
54	Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients. <i>Oncotarget</i> , 2016, 7, 53299-53308.	1.8	9

#	ARTICLE	IF	CITATIONS
55	DNA polymerase I proofreading exonuclease activity is required for endonuclease V repair pathway both in vitro and in vivo. DNA Repair, 2018, 64, 59-67.	2.8	8
56	The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Scientific Reports, 2021, 11, 12084.	3.3	7
57	The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan. Targeted Oncology, 2022, 17, 295-306.	3.6	7
58	Copy Number Alterations of Depressed Colorectal Neoplasm Predict the Survival and Response to Oxaliplatin in Proximal Colon Cancer. Cancers, 2020, 12, 1527.	3.7	5
59	Measurement of uracil-DNA glycosylase activity by matrix assisted laser desorption/ionization time-of-flight mass spectrometry technique. DNA Repair, 2021, 97, 103028.	2.8	5
60	Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment. Cancer Research and Treatment, 2018, 50, 1164-1174.	3.0	5
61	Application of single nucleotide extension and MALDI-TOF mass spectrometry in proofreading and DNA repair assay. DNA Repair, 2018, 61, 63-75.	2.8	4
62	Proofreading and DNA Repair Assay Using Single Nucleotide Extension and MALDI-TOF Mass Spectrometry Analysis. Journal of Visualized Experiments, 2018, , .	0.3	4
63	Transthyretin as a Biomarker to Predict and Monitor Major Depressive Disorder Identified by Whole-Genome Transcriptomic Analysis in Mouse Models. Biomedicines, 2021, 9, 1124.	3.2	4
64	Novel Genetic Prognostic Signature for Lung Adenocarcinoma Identified by Differences in Gene Expression Profiles of Low- and High-Grade Histological Subtypes. Biomolecules, 2022, 12, 160.	4.0	4
65	Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients. Journal of Thoracic Disease, 2016, 8, 86-92.	1.4	2
66	Proofreading of single nucleotide insertion/deletion replication errors analyzed by MALDI-TOF mass spectrometry assay. DNA Repair, 2020, 88, 102810.	2.8	1
67	Multiplex ALK, RET, and ROS1 fusion mutation detection in FFPE from lung cancer patients by MALDI-TOF mass spectrometry.. Journal of Clinical Oncology, 2017, 35, e13103-e13103.	1.6	0
68	MIP-1 $\beta$ and SDF-1 $\alpha$ Confer to High-Fat Diet Enhanced Lung Adenocarcinoma Progression. SSRN Electronic Journal, 0, , .	0.4	0
69	Improvement of NGS uniformity of single cell sequencing in CTCs by WGA QC and increased sequencing throughput.. Journal of Clinical Oncology, 2018, 36, e21176-e21176.	1.6	0
70	Copy Number Alterations Predict the Survival of Early Colorectal Cancer with Depressed Morphology. SSRN Electronic Journal, 0, , .	0.4	0
71	Genetic Deletion of HJ1 Does Not Affect Blood Coagulation in Mice. International Journal of Molecular Sciences, 2022, 23, 2064.	4.1	0
72	Uracil-DNA Glycosylase Assay by Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry Analysis. Journal of Visualized Experiments, 2022, , .	0.3	0

#	ARTICLE	IF	CITATIONS
73	Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid. Cancers, 2022, 14, 2824.	3.7	0